Compare DRS & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRS | ELAN |
|---|---|---|
| Founded | 1969 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.3B |
| IPO Year | N/A | 2018 |
| Metric | DRS | ELAN |
|---|---|---|
| Price | $34.43 | $21.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $46.83 | $22.11 |
| AVG Volume (30 Days) | 888.1K | ★ 4.9M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.99 | 0.07 |
| Revenue | $3,569,000,000.00 | ★ $4,591,000,000.00 |
| Revenue This Year | $11.94 | $7.19 |
| Revenue Next Year | $6.66 | $5.32 |
| P/E Ratio | ★ $34.83 | $300.24 |
| Revenue Growth | ★ 12.27 | 3.08 |
| 52 Week Low | $28.17 | $8.02 |
| 52 Week High | $49.31 | $23.70 |
| Indicator | DRS | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 44.60 |
| Support Level | $33.68 | $20.41 |
| Resistance Level | $34.90 | $21.86 |
| Average True Range (ATR) | 0.75 | 0.65 |
| MACD | 0.35 | -0.20 |
| Stochastic Oscillator | 73.95 | 25.38 |
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.